References
- Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite APS. J Thromb Haemost 2006; 4(2)295–306
- Piette J-C, Wechsler B, Frances C, Papo T, Godeau P. Exclusion criteria for primary APS. J Rheumatol 1993; 20: 1802–1803
- Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. PAPS as the forerunner of SLE. Lupus 2007; 16: 324–328
- Andreoli L, Pregnolato F, Burlingame RW, Allegri F, Rizzini S, Fanelli V, Radice A, Corace C, Sinico RA, Meroni PL, Tincani A. ANuc in PAPS: A hint at systemic autoimmunity?. J Autoimmun 2008; 30: 51–57
- Shoenfeld Y. APS—More systemic disease than SLE. Clin Rev Allergy Immunol 2007; 32: 129–130
- Laskin CA, Clark CA, Spitzer KA. APS in SLE: Is the whole greater than the sum of its parts?. Rheumatic Disease Clinics of North America 2005; 31: 255–272
- Ruiz-Irastorza G, Egurbide MV, Ugalde J, Aguirre C. High impact of APS on irreversible organ damage and survival of patients with SLE. Arch Intern Med 2004; 164: 77–82
- Gerosa M, Chighizola C, Meroni PL. Aspirin in asymptomatic patients with confirmed positivity of APL? Yes (in some cases). Intern Emerg Med 2008; 3(3)201–203
- Finazzi G. Aspirin in asymptomatic patients with confirmed positivity of APL? No. Intern Emerg Med 2008; 3(3)197–200
- Ruiz-Irastorza G, Egurbide M-V, Pijoan J-I, Garmendia M, Villar I, Martinez-Berriotxoa A, Erdozain J-G, Aguirre C. Effect of antimalarians on thrombosis and survival in patients with SLE. Lupus 2006; 15: 577–583
- Moroni G, Ventura D, Riva P, Panzeri P, Quaglini S, Banfi G, Simonini P, Bader R, Meroni PL, Ponticelli C. APL are associated with an increased risk for cronica renal insufficiency in patients with lupus nephritis. Am J Kidney Dis 2004; 43(1)28–36
- Tomietto P, Annese V, D'Agostini S, Venturini P, La Torre G, De Vita S, Ferraccioli GF. General and specific factors associated with severity of cognitive impairment in SLE. Arthritis Rheum 2007; 57: 1461–1472
- Mikdashi J, Handwerger B. Predictors of neuropsychiatric damage in SLE: Data from the Maryland lupus cohort. Rheumatology (Oxford) 2004; 43: 1555–1560
- Descloux E, Durieu I, Cochat P, Vital Durand D, Ninet J, Fabien N, Cimaz R. Paedriatic SLE: Prognostic impact of APL. Rheumatology (Oxford) 2008; 47(2)183–187
- Tincani A, Franceschini F, Spunghi M, Panzeri P, Balestrieri G, Meroni PL. Immunological abnormalities in the APS. The APS II: Autoimmune Thrombosis, RA Asherson, R Cervera, JC Piette, Y Shoenfeld. Elsevier, Amsterdam 2002; 271–284
- Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apo in the pathogenesis of SLE. Lupus 2008; 17(5)371–375
- Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, et al. Apo cell clearance in SLE. I. Opsonization by APL. Arthritis Rheum 1998; 41: 205–214
- Pascual V, Farkas L, Banchereau J. SLE: All roads lead to type I interferons. Curr Opin Immunol 2006; 18: 676–682
- Cavazzana I, Nebuloni M, Cetin I, Acaia B, Saino S, Borghi MO, Tincani A, Meroni PL. Complement activation in APS: A clue for an inflammatory process?. J Autoimmun 2007; 28: 160–164
- Atsumi T, Amengual O. Genetics of APS. Hughes syndrome: Antiphospholipid syndrome2nd ed., MA Khamashta. Springer-Verlag, London 2006; 521